PT  - JOURNAL ARTICLE
AU  - Mothes, Ronja
AU  - Pascual-Reguant, Anna
AU  - Koehler, Ralf
AU  - Liebeskind, Juliane
AU  - Liebheit, Alina
AU  - Bauherr, Sandy
AU  - Dittmayer, Carsten
AU  - Laue, Michael
AU  - von Manitius, Regina
AU  - Elezkurtaj, Sefer
AU  - Durek, Pawel
AU  - Heinrich, Frederik
AU  - Heinz, Gitta Anne
AU  - Guerra, Gabriela Maria
AU  - Obermayer, Benedikt
AU  - Meinhardt, Jenny
AU  - Ihlow, Jana
AU  - Radke, Josefine
AU  - Heppner, Frank L.
AU  - Enghard, Philipp
AU  - Stockmann, Helena
AU  - Aschman, Tom
AU  - Schneider, Julia
AU  - Corman, Victor
AU  - Sander, Leif Erik
AU  - Mashreghi, Mir-Farzin
AU  - Conrad, Thomas
AU  - Hocke, Andreas
AU  - Niesner, Raluca A.
AU  - Radbruch, Helena
AU  - Hauser, Anja E.
TI  - Local CCL18 and CCL21 expand lung fibrovascular niches and recruit lymphocytes, leading to tertiary lymphoid structure formation in prolonged COVID-19
AID  - 10.1101/2022.03.24.22272768
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.24.22272768
4099  - http://medrxiv.org/content/early/2022/03/27/2022.03.24.22272768.short
4100  - http://medrxiv.org/content/early/2022/03/27/2022.03.24.22272768.full
AB  - Post-acute lung sequelae of COVID-19 are challenging many survivors across the world, yet the mechanisms behind are poorly understood. Our results delineate an inflammatory cascade of events occurring along disease progression within fibrovascular niches. It is initiated by endothelial dysfunction, followed by heme scavenging of CD163+ macrophages and production of CCL18. This chemokine synergizes with local CCL21 upregulation to influence the stromal composition favoring endothelial to mesenchymal transition. The local immune response is further modulated via recruitment of CCR7+ T cells into the expanding fibrovascular niche and imprinting an exhausted, T follicular helper–like phenotype in these cells. Eventually, this culminates in the formation of tertiary lymphoid structures, further perpetuating chronic inflammation. Thus, our work presents misdirected immune-stromal interaction mechanisms promoting a self-sustained and non-resolving local immune response that extends beyond active viral infection and leads to profound tissue repurposing and chronic inflammation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by funding from the Deutsche Forschungsgemeinschaft, HA5354/10-1, SPP1937 (HA5354/8-2) and TRR130 P17 to A.E.H., TRR 130 C01 and SFB 1444 P14 (to A.E.H. and R.N.). R.A.N. was supported by DFG 1167/5-1. H.R. was supported by DFG (RA 2491/1-1 and CRC 130 TP17). A.H. was supported by Berlin University Alliance GC2 Global Health (Corona Virus Pre-Exploration Project), BMBF (RAPID and Organo-Strat, alvBarriere-COVID-19) as well as DFG (SFB-TR 84, B6 / Z1a), by the Berlin Institute of Health (BIH), Charite 3 R, and Charite-Zeiss MultiDim. S.E., F.H., H.R. and R.M. were supported by BMBF (Defeat Pandemics, Organo-Strat), F.H. was supported by DFG under Germany Excellence Strategy EXC-2049-390688087, as well as SFB TRR 167 and HE 3130/6-1. B.O. was funded through the BIH Clinical Single Cell Bioinformatics Pipeline. Furthermore, we thank the Charite Foundation (Max Rubner Preis 2016) for financial support to C.D.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted in accordance with the declaration of Helsinki and with the approval of the Ethics Committee of the Charite (EA 1/144/927 13, EA2/066/20 and EA1/317/20) and the Charite - BIH COVID-19 research board. Autopsies were performed on the legal basis of 1 926 SRegG BE of the autopsy act of Berlin and 25(4) of the German Infection Protection Act.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified human/patient spatial transcriptomics data have been deposited at Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/), under record GSE190732, and are available for reviewers. Microscopy data, as well as any additional information required to re-analyze the data reported in this paper will be shared by the lead contact upon reasonable request. https://www.ncbi.nlm.nih.gov/geo/